Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch Eton Pharmaceuticals' ET-600 met bioequivalence standards in a study, with an FDA filing planned for April 2025 and a potential launch in early 2026.
3 Stocks Insiders Are Buying Heavily In October 2024, And Why Should investors add these stocks on their watchlist? Insider buys suggest so.
Is NASDAQ:ETON suited for growth investing? ETON PHARMACEUTICALS INC (
NASDAQ:ETON ) may be suited for growth investing, we'll explore why in this article.
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.
ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023 ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Gilead Sciences Tops Q3 Earnings And Revenue Estimates While Gilead has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?
Earnings Scheduled For March 14, 2024 Companies Reporting Before The Bell • Pharming (
NASDAQ:PHAR ) is projected to report earnings for its fourth quarter.
